PMID- 33082331
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 2055-1010 (Electronic)
IS  - 2055-1010 (Linking)
VI  - 30
IP  - 1
DP  - 2020 Oct 20
TI  - Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD 
      patients.
PG  - 47
LID - 10.1038/s41533-020-00207-7 [doi]
LID - 47
AB  - This study reports the association of ICS use and the risk of type 2 diabetes 
      mellitus (T2DM) in Swedish patients with COPD using data from real-world, primary 
      care settings. A total of 7078 patients with COPD were included in this analysis 
      and the 5-year cumulative incidence rate per 100,000 person years was 1506.9. The 
      yearly incidence rate per 100,000 person years ranged from 850 to 1919. Use of 
      ICS especially at a high dose in patients with COPD was related to an increased 
      risk of T2DM.
FAU - Stallberg, Bjorn
AU  - Stallberg B
AUID- ORCID: 0000-0001-8497-7326
AD  - Department of Public Health and Caring Sciences, Family Medicine and Preventive 
      Medicine, Uppsala University, Uppsala, Sweden. b.stallberg@telia.com.
FAU - Janson, Christer
AU  - Janson C
AD  - Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala 
      University, Uppsala, Sweden.
FAU - Lisspers, Karin
AU  - Lisspers K
AD  - Department of Public Health and Caring Sciences, Family Medicine and Preventive 
      Medicine, Uppsala University, Uppsala, Sweden.
FAU - Johansson, Gunnar
AU  - Johansson G
AD  - Department of Public Health and Caring Sciences, Family Medicine and Preventive 
      Medicine, Uppsala University, Uppsala, Sweden.
FAU - Gutzwiller, Florian S
AU  - Gutzwiller FS
AUID- ORCID: 0000-0001-7754-5744
AD  - Novartis Pharma AG, Basel, Switzerland.
FAU - Mezzi, Karen
AU  - Mezzi K
AD  - Novartis Pharma AG, Basel, Switzerland.
FAU - Bjerregaard, Bine Kjoeller
AU  - Bjerregaard BK
AUID- ORCID: 0000-0002-5233-5481
AD  - IQVIA Solutions, Copenhagen, Denmark.
FAU - Kejs, Anne Mette Tranberg
AU  - Kejs AMT
AD  - IQVIA Solutions, Copenhagen, Denmark.
FAU - Jorgensen, Leif
AU  - Jorgensen L
AD  - IQVIA Solutions, Copenhagen, Denmark.
FAU - Larsson, Kjell
AU  - Larsson K
AD  - Integrative Toxicology, The National Institute of Environmental Medicine, 
      Karolinska Institutet, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201020
PL  - England
TA  - NPJ Prim Care Respir Med
JT  - NPJ primary care respiratory medicine
JID - 101631999
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Bronchodilator Agents)
SB  - IM
MH  - Administration, Inhalation
MH  - Adrenal Cortex Hormones/administration & dosage/*adverse effects/therapeutic use
MH  - Aged
MH  - Bronchodilator Agents/administration & dosage/*adverse effects/therapeutic use
MH  - Diabetes Mellitus, Type 2/*chemically induced/epidemiology
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy
MH  - Risk Factors
MH  - Sweden/epidemiology
PMC - PMC7576803
COIS- B.S. reports personal fees from AstraZeneca, Novartis, Boehringer Ingelheim, 
      GlaxoSmithKline, Meda, Teva, and Chiesi, outside the submitted work. C.J. reports 
      personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, 
      Novartis, and Teva, outside the submitted work. K. Lisspers reports personal fees 
      from AstraZeneca, Novartis, Boehringer Ingelheim, GlaxoSmithKline, and Chiesi, 
      outside the submitted work. G.J. has participated in the steering committee 
      organised by Novartis for this study and served on advisory boards arranged by 
      AstraZeneca, Novo Nordisk, and Takeda. F.S.G. and K.M. are employees of Novartis 
      Pharma AG. B.K.B., L.J., and A.M.T.K. are employees of IQVIA and have received 
      remuneration in relation to statistical analyses. K. Larsson has, during the past 
      5 years, on one or more occasion served in an advisory board, served as a 
      speaker, and/or participated in education activities arranged by AstraZeneca, 
      Boehringer Ingelheim, GlaxoSmithKline, Chiesi, Sanofi, Novartis, Orion, and Teva.
EDAT- 2020/10/22 06:00
MHDA- 2021/09/02 06:00
PMCR- 2020/10/20
CRDT- 2020/10/21 05:55
PHST- 2020/07/02 00:00 [received]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/10/21 05:55 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
PHST- 2020/10/20 00:00 [pmc-release]
AID - 10.1038/s41533-020-00207-7 [pii]
AID - 207 [pii]
AID - 10.1038/s41533-020-00207-7 [doi]
PST - epublish
SO  - NPJ Prim Care Respir Med. 2020 Oct 20;30(1):47. doi: 10.1038/s41533-020-00207-7.